230 related articles for article (PubMed ID: 17714734)
1. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Tang ZY; Wu YL; Gao SL; Shen HW
J Surg Res; 2008 Mar; 145(1):111-23. PubMed ID: 17714734
[TBL] [Abstract][Full Text] [Related]
2. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
4. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
Guo Q; Chen Y; Wu Y
Tumori; 2009; 95(6):796-803. PubMed ID: 20210246
[TBL] [Abstract][Full Text] [Related]
5. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
Chandler NM; Canete JJ; Callery MP
J Gastrointest Surg; 2004 Dec; 8(8):1072-8. PubMed ID: 15585396
[TBL] [Abstract][Full Text] [Related]
6. Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
Torres C; Linares A; Alejandre MJ; Palomino-Morales RJ; Delgado JR; Perales S
Pancreas; 2016 Feb; 45(2):269-80. PubMed ID: 26495790
[TBL] [Abstract][Full Text] [Related]
7. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
[TBL] [Abstract][Full Text] [Related]
8. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
Wang M; Lu X; Dong X; Hao F; Liu Z; Ni G; Chen D
World J Surg Oncol; 2015 Feb; 13():66. PubMed ID: 25880226
[TBL] [Abstract][Full Text] [Related]
9. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
[TBL] [Abstract][Full Text] [Related]
10. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Lee JK; Ryu JK; Yang KY; Woo SM; Park JK; Yoon WJ; Lee SH; Jeong KS; Kim YT; Yoon YB
Pancreas; 2011 Aug; 40(6):966-73. PubMed ID: 21487323
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Bold RJ; Virudachalam S; McConkey DJ
J Surg Res; 2001 Sep; 100(1):11-7. PubMed ID: 11516199
[TBL] [Abstract][Full Text] [Related]
12. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets.
Zhang W; Chen H; Liu DL; Li H; Luo J; Zhang JH; Li Y; Chen KJ; Tong HF; Lin SZ
Int J Oncol; 2013 Apr; 42(4):1189-96. PubMed ID: 23440366
[TBL] [Abstract][Full Text] [Related]
13. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
16. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Fahy BN; Schlieman MG; Virudachalam S; Bold RJ
J Surg Res; 2003 Jul; 113(1):88-95. PubMed ID: 12943815
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Märten A; Zeiss N; Serba S; Mehrle S; von Lilienfeld-Toal M; Schmidt J
Mol Cancer Ther; 2008 Nov; 7(11):3624-31. PubMed ID: 19001444
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Vaziri SA; Grabowski DR; Hill J; Rybicki LR; Burk R; Bukowski RM; Ganapathi MK; Ganapathi R
Anticancer Res; 2009 Aug; 29(8):2961-9. PubMed ID: 19661301
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.
Chien W; Ding LW; Sun QY; Torres-Fernandez LA; Tan SZ; Xiao J; Lim SL; Garg M; Lee KL; Kitajima S; Takao S; Leong WZ; Sun H; Tokatly I; Poellinger L; Gery S; Koeffler PH
Oncotarget; 2014 Jul; 5(13):4881-94. PubMed ID: 24952679
[TBL] [Abstract][Full Text] [Related]
20. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
